In a post by Rami Manochakian on Twitter, it says, “Just published NEJM Results of NADIM II, phase 2 clinical trial, comparing Neoadjuvant nivolumab plus chemotherapy vs chemotherapy alone in patients with resectable stage IIIA or IIIB Non-Small Cell Lung Cancer.”
For article: Click here
Source: Rami Manochakian/Twitter